| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
|
Purity: ≥98%
Mildronate (Quaterin; Meldonium; Kvaterin; Mildronate), a structural analogue of gammabutyrobetaine and performance-enhancing drug developed by Latvia Institute of Organic Synthesis, is a potent inhibitor of biosynthesis of L-carnitine by gamma-butyrobetaine (GBB) hydroxylase, also a competitive inhibitor of renal carnitine reabsorption.
| ln Vitro |
By targeting PFKP to regulate glycolysis and consequently promote Nrf2's translocation from the cytoplasm to the nucleus, medonium (20–40 μM; 24 hours) reduces lung injury and mitigates oxidative stress and mitochondrial damage under hypoxic settings [3].
|
||
|---|---|---|---|
| ln Vivo |
In mice, meldonium (50, 100, or 200 mg/kg; once daily for three days) moderately lessens lung damage brought on by hypoxia [3].
|
||
| Cell Assay |
RT-PCR[3]
Cell Types: Rat alveolar type II epithelial RLE-6TN cells in hypoxia incubator Tested Concentrations: 20, or 40 μM Incubation Duration: 24 h Experimental Results: Dramatically diminished the mRNA expression of PFKP, PDK1, and PKM2 compared with the hypoxia group. Western Blot Analysis[3] Cell Types: Rat alveolar type II epithelial RLE-6TN cells in hypoxia incubator Tested Concentrations: 20, or 40 μM Incubation Duration: 24 h Experimental Results: Dramatically decreased the protein expression of PFKP, PKM2, and LDHA . |
||
| Animal Protocol |
|
||
| References |
|
||
| Additional Infomation |
Meldonium is an ammonium betaine that is beta-alaninate in which one of the amino hydrogens is replaced by a trimethylamino group. A clinically used cardioprotective drug that is used for treatment of heart failure, myocardial infarction, arrhythmia, atherosclerosis and diabetes. It has a role as a cardioprotective agent, a neuroprotective agent and an EC 1.14.11.1 (gamma-butyrobetaine dioxygenase) inhibitor.
|
| Molecular Formula |
C6H14N2O2
|
|
|---|---|---|
| Molecular Weight |
147.19
|
|
| Exact Mass |
146.105
|
|
| CAS # |
76144-81-5
|
|
| Related CAS # |
Meldonium dihydrate;86426-17-7
|
|
| PubChem CID |
123868
|
|
| Appearance |
White to off-white solid powder
|
|
| Melting Point |
85-90ºC
|
|
| Index of Refraction |
1.598
|
|
| LogP |
-2.1
|
|
| Hydrogen Bond Donor Count |
1
|
|
| Hydrogen Bond Acceptor Count |
3
|
|
| Rotatable Bond Count |
3
|
|
| Heavy Atom Count |
10
|
|
| Complexity |
112
|
|
| Defined Atom Stereocenter Count |
0
|
|
| InChi Key |
PVBQYTCFVWZSJK-UHFFFAOYSA-N
|
|
| InChi Code |
InChI=1S/C6H14N2O2/c1-8(2,3)7-5-4-6(9)10/h7H,4-5H2,1-3H3
|
|
| Chemical Name |
3-[(trimethylazaniumyl)amino]propanoate
|
|
| Synonyms |
|
|
| HS Tariff Code |
2934.99.9001
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|||
|---|---|---|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 100 mg/mL (684.04 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
(Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 6.7939 mL | 33.9697 mL | 67.9394 mL | |
| 5 mM | 1.3588 mL | 6.7939 mL | 13.5879 mL | |
| 10 mM | 0.6794 mL | 3.3970 mL | 6.7939 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT01831011 | Completed | Drug: mildronate injection Drug: cinepazide maleate injection |
Acute Ischemic Stroke | Xijing Hospital | July 2008 | Phase 2 |
| NCT05689827 | Completed | Drug: Ethyl methyl hydroxypyridine succinate + Meldonium |
Asthenia COVID-19 |
Promomed, LLC | April 5, 2022 | Phase 4 |
| NCT05939622 | Completed | Drug: Ethyl methyl hydroxypyridine succinate + Meldonium |
Asthenia COVID-19 |
Promomed, LLC | May 18, 2022 | Phase 4 |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA
